Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — Shareholder Meeting (July 2022)
11 slides from Jazz Pharmaceuticals's shareholder meeting presentation, Jul 7, 2022
Slide 1: 2022 Annual General Meeting
2022 Annual General Meeting Innovating to Transform the Lives of Patients and Their Families July 2022 Grace Epidiolex patient
Slide 2: Caution Concerning Forward-Looking Statements
Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, in
Slide 3: Our Purpose / Who We Are
ALL = acute lymphoblastic leukemia, IH = idiopathic hypersomnia Casey Xywav IH Patient Leighton Rylaze ALL Trial Participant Our Purpose Who We Are is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious disea
Slide 4: Track Record of Strong Execution
Track Record of Strong Execution Products launched or acquired since 2019. 2L = second-line, IH = idiopathic hypersomnia, SCLC = small cell lung cancer Leading neuroscience franchises Significant growth opportunity with blockbuster potential Treatment of choice in 2L SCLC in 2020 - 2021 5 key produc
Slide 5: Vision 2025: Deliver Sustainable Growth and Enhanced Value
Vision 2025: Deliver Sustainable Growth and Enhanced Value Vision 2025 represents Jazz estimates of future performance PIPELINE Pipeline potentially delivering multiple novel product approvals by end of the decade COMMERCIAL Substantial revenue target for 2025 OPERATIONAL EXCELLENCE Operational exce
Slide 6: Track Record of Revenue Growth
Track Record of Revenue Growth CAGR = compound annual growth rate. Grace Epidiolex Patient GUIDED BY OUR PATIENT-CENTRIC APPROACH 2005 – 2021: YoY revenue growth for 16 consecutive years 2016 – 2021: 16% CAGR Revenue $ in millions $3,094
Slide 7: Consistently Enhancing our ESG Strategy
Consistently Enhancing our ESG Strategy UN SDGs = United Nations Sustainable Development Goals SASB = Sustainability Accounting Standards Board We are committed to advancing our ESG Strategy, building upon previous third-party materiality assessments and will seek to report against the upcoming Inte
Slide 8: 2022 Annual General Meeting Proposals
2022 Annual General Meeting Proposal 1 Election of Directors Auditor Appointment and Remuneration Proposal 2 Authority to Issue Shares for Cash Without First Offering Shares to Existing Shareholders (see slides 9-11) Proposal 4 Proposal 3 “Say-on-Pay” Proposal 5 Meeting Adjournment Under Irish law,
Slide 9: Responding to Shareholder Feedback on Proposal 4
Responding to Shareholder Feedback on Proposal 4 OUR PROPOSED AUTHORITY AT THE 2022 AGM IS MEANINGFULLY MORE LIMITED THAN THE AUTHORITY SOUGHT AT THE 2021 AGM WHILE PROVIDING US WITH A LEVEL OF FLEXIBILITY TO EXECUTE ON OUR CURRENT STRATEGY FOR GROWTH Shareholder Engagement Proposal 4: 2022 Proposed
Slide 10: How does the 2022 AGM Proposal compare with the 2021 AGM Proposal
How does the 2022 AGM Proposal compare with the 2021 AGM Proposal 2021 AGM Proposal Max Authorised but Unissued Share Capital 5 years 0 1 year 2 years 3 years 4 years 5 years 18 months 2022 AGM Proposal 20% Issued Share Capital 300 62 12 0 1 year 2 years 3 years 4 years 5 years Current Issued Share
Slide 11: Why our Shareholders should approve Proposal 4
Why our Shareholders should approve Proposal 4 1 3 2 Vital flexibility for how we intend to advance our business During our more than ten years as an Irish-incorporated company, we have demonstrated disciplined use of equity in furtherance of our strategy for growth Supports Vision 2025’s Delivery o
Jazz Pharmaceuticals — Shareholder Meeting (July 2022) on 6ix